Pan-cancer analysis reveals the relationship between RCSD1 immune infiltration and clinical prognosis in human tumors

BackgroundRCSD1 is a cytoskeletal regulator that has been confirmed to undergo genetic mutations in hematological tumors, but the mechanisms of RCSD1 in pan-cancer and its impact on patient prognosis have not been studied. MethodsUsing TCGA, GEPIA, UALCAN, Kaplan-Meier plotters, Linkedomics, String, cBioPortal, TISIDB, TCIA and TIMER database methods, we investigated the expression of RCSD1 in human tumors and its relationship to clinical prognosis, functional analysis of co-expression networks, mutation status, and immune infiltration in cancers, especially lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC). ResultsThe expression of RCSD1 is low in most tumors compared with normal tissues, and its high expression is associated with good patient survival. The RCSD1 co-expression network is mainly involved in the regulation of immune response. In human cancer, RCSD1 plays an important role in the tumor microenvironment (TME) and is significantly associated with the expression of immune infiltrating cells (TIL) in lung cancer. ConclusionsAs a prognostic biomarker of generalized cancer, RCSD1 is associated with immune infiltration.

Automated summary

The study reveals that RCSD1 is expressed at low levels in most tumors, but its high expression is associated with good patient survival. The co-expression network of RCSD1 is mainly involved in the regulation of immune response and plays a significant role in the tumor microenvironment and immune infiltrating cells in lung cancer.